We evaluated myeloma cell lines (MM.1S, OPM-2, AMO1) and primary bone marrow aspirate samples from 5 relapsed/refractory myeloma patients, selected on CD19−/CD138+ plasma cells. Here, CD19 is linked to plasma cell myeloma.